Dupilumab therapy following JAK inhibitor withdrawal in moderate-severe atopic dermatitis

Dermatol Ther. 2022 Oct;35(10):e15750. doi: 10.1111/dth.15750. Epub 2022 Aug 8.

Authors

Lisa Kiely¹, Cathal O'Connor^{1

2}, Michelle Murphy^{1

2}

Affiliations

¹ Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland.
² Department of Medicine, University College, Cork, Ireland.

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Janus Kinase Inhibitors* / adverse effects
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Janus Kinase Inhibitors
dupilumab